SEC Form 4 · accession 0001209191-17-059630
Dimension Therapeutics, Inc. · DMTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
George V Migausky
Director
Period of report
Nov 7, 2017
Accepted (ET)
Nov 7, 2017 · 5:09 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001592288
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $4.09 | Nov 7, 2017 | D | 55,772 | D | — | Jun 2, 2025 | Common Stock | 55,772 | 0 | D |
| Stock Option (Right to Buy)F2 | $7.08 | Nov 7, 2017 | D | 32,069 | D | — | May 18, 2026 | Common Stock | 32,069 | 0 | D |
| Stock Option (Right to Buy)F3 | $1.15 | Nov 7, 2017 | D | 17,000 | D | — | May 24, 2027 | Common Stock | 17,000 | 0 | D |
Explanation of responses
- F1This stock option, which vests in equal monthly installments over 48 months beginning June 3, 2015, was assumed by Ultragenyx Pharmaceutical Inc. ("Ultragenyx"), and converted in accordance with the exchange ratio as set forth in the Agreement and Plan of Merger dated October 2, 2017 between the Issuer, Ultragenyx and Mystic River Merger Sub Inc., a direct, wholly-owned subsidiary of Ultragenyx.
- F2These options were assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement.
- F3These options, which vest in full on the earlier of May 25, 2018 or the Issuer's next annual meeting of stockholders, subject to the director's continued service on the Board, were assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement.